Heather A. Lillemoe
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Heather A. Lillemoe has a total of 119 co-authors. Here are the top co-authors by number of shared publications:
Christopher P. Scally
Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, USA
5 shared publicationsB. Ashleigh Guadagnolo
Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, USA
4 shared publications- Ching-Wei D. Tzeng
Department of Surgical Oncology The University of Texas MD Anderson Cancer Center Houston Texas USA
4 shared publications - Jean-Nicolas Vauthey
Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
4 shared publications Kelly K. Hunt
Department of Breast Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, USA
4 shared publications- Brittany C. Fields
Department of Surgical Oncology, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX
3 shared publications
Latest Publications
- 30 October 2026
- Published by Springer Nature in Annals of Surgical Oncology
- p. 1-2
ASO Visual Abstract: Primary Breast Angiosarcoma: Clinicopathologic Features and Oncologic Outcomes
- 30 October 2026
- Published by Springer Nature in Annals of Surgical Oncology
- p. 1-2
ASO Visual Abstract: Primary Breast Angiosarcoma: Clinicopathologic Features and Oncologic Outcomes
- Open Access
- 27 October 2026
- Published by UT MD Anderson Cancer Center Research Medical Library in Advances in Cancer Education and Quality Improvement
- Vol. 2  (2) , 14
Aligning Trainee Leave Policies Across Surgical Fellowships: Development of a Division-Wide Framework for Leave and Program Completion
Background: Surgical fellows and program leaders face difficulties navigating parental, caregiver, medical, and personal leave due to variation in policies. A Division of Surgery (DoS) Trainee Leave and Parental Support Task Force was convened at The University of Texas MD Anderson Cancer Center to review existing requirements and develop a harmonized framework for trainee leave and fellowship program completion. Methods: The Task Force conducted a comprehensive review of policies relevant to surgical fellow leave and graduation requirements, identified best practices, and drafted a DoS policy. The policy was refined iteratively through engagement with key stakeholders, including program directors, department chairs, division leadership, and the Graduate Medical Education (GME) Office. Results: The policy review highlighted substantial variation among surgical fellowship programs in their governing bodies, leave policies, and training requirements. Major organizations were aligned with the institutional GME policy providing 6 weeks of leave but differed in recommendations regarding protected vacation time and time-based graduation requirements. A DoS policy was developed in accordance with best practices, with specification of the minimum number of weeks of clinical activity necessary to graduate on time from fellowships of different durations. After revision by key stakeholders, the final policy was approved for implementation in the 2026-2027 academic year. Conclusion: A structured policy-harmonization process can promote clarity about surgical trainee leave options while ensuring academic rigor and compliance with specialty board requirements.
- 27 October 2026
- Published by UT MD Anderson Cancer Center Research Medical Library in Advances in Cancer Education and Quality Improvement
- Vol. 2  (2) , 14
Open AccessAligning Trainee Leave Policies Across Surgical Fellowships: Development of a Division-Wide Framework for Leave and Program Completion
Background: Surgical fellows and program leaders face difficulties navigating parental, caregiver, medical, and personal leave due to variation in policies. A Division of Surgery (DoS) Trainee Leave and Parental Support Task Force was convened at The University of Texas MD Anderson Cancer Center to review existing requirements and develop a harmonized framework for trainee leave and fellowship program completion. Methods: The Task Force conducted a comprehensive review of policies relevant to surgical fellow leave and graduation requirements, identified best practices, and drafted a DoS policy. The policy was refined iteratively through engagement with key stakeholders, including program directors, department chairs, division leadership, and the Graduate Medical Education (GME) Office. Results: The policy review highlighted substantial variation among surgical fellowship programs in their governing bodies, leave policies, and training requirements. Major organizations were aligned with the institutional GME policy providing 6 weeks of leave but differed in recommendations regarding protected vacation time and time-based graduation requirements. A DoS policy was developed in accordance with best practices, with specification of the minimum number of weeks of clinical activity necessary to graduate on time from fellowships of different durations. After revision by key stakeholders, the final policy was approved for implementation in the 2026-2027 academic year. Conclusion: A structured policy-harmonization process can promote clarity about surgical trainee leave options while ensuring academic rigor and compliance with specialty board requirements.
- Open Access
- 12 October 2026
- Published by Springer Nature in Annals of Surgical Oncology
- p. 1-8
Primary Breast Angiosarcoma: Clinicopathologic Features and Oncologic Outcomes
Background: Primary breast angiosarcoma (PBA) is rare, and limited data exist because studies often combine primary and secondary angiosarcoma patients. Methods: For patients with PBA who received care at a comprehensive cancer center from 1991 to 2025 and underwent surgical resection, this retrospective study collected and analyzed clinicopathologic features, treatment patterns, and survival data. Results: Among 176 patients, 138 met the inclusion criteria. The median age was 40 years (interquartile range [IQR], 32â49 years). Most of the tumors were high grade with a median size of 6.5 cm. Most of the patients underwent mastectomy (88%). Among the 50 patients (36%) who underwent axillary surgery, only 6 patients had nodal metastases. Multimodal treatment was performed for 121 patients (88%), including chemotherapy/surgery ( n = 46, 38%), radiation therapy (RT)/surgery ( = 15, 12%), and chemotherapy/RT/surgery ( n = 60, 50%). The median follow-up time was 3.7 years. The median overall survival (OS) was 6 years (IQR, 3.5â8.7 years), and the 5-year OS was 58%. Recurrence was experienced by 62% of the patients, with a median recurrence-free survival (RFS) of 3 years (IQR, 1.4â7.7 years). Most of the recurrences were distant (79%), with 14% of the patients experiencing local recurrence only. Tumor size larger than 5 cm and high-grade histology were independently associated with lower OS. When stratified by treatment modality, there was no statistical difference in OS ( p = 0.475). Conclusions: Primary breast angiosarcoma arises in women with a median age of 40 years, and large, high-grade tumors are associated with worse survival outcomes. Distant recurrence is common, whereas nodal metastases and local failure are not. Most of the patients in this study received multimodal therapy without a clear impact of modality on OS. However, further collaborative studies may be required to assess the impact of modality on disease outcomes.
- 12 October 2026
- Published by Springer Nature in Annals of Surgical Oncology
- p. 1-8
Open AccessPrimary Breast Angiosarcoma: Clinicopathologic Features and Oncologic Outcomes
Background: Primary breast angiosarcoma (PBA) is rare, and limited data exist because studies often combine primary and secondary angiosarcoma patients. Methods: For patients with PBA who received care at a comprehensive cancer center from 1991 to 2025 and underwent surgical resection, this retrospective study collected and analyzed clinicopathologic features, treatment patterns, and survival data. Results: Among 176 patients, 138 met the inclusion criteria. The median age was 40 years (interquartile range [IQR], 32â49 years). Most of the tumors were high grade with a median size of 6.5 cm. Most of the patients underwent mastectomy (88%). Among the 50 patients (36%) who underwent axillary surgery, only 6 patients had nodal metastases. Multimodal treatment was performed for 121 patients (88%), including chemotherapy/surgery ( n = 46, 38%), radiation therapy (RT)/surgery ( = 15, 12%), and chemotherapy/RT/surgery ( n = 60, 50%). The median follow-up time was 3.7 years. The median overall survival (OS) was 6 years (IQR, 3.5â8.7 years), and the 5-year OS was 58%. Recurrence was experienced by 62% of the patients, with a median recurrence-free survival (RFS) of 3 years (IQR, 1.4â7.7 years). Most of the recurrences were distant (79%), with 14% of the patients experiencing local recurrence only. Tumor size larger than 5 cm and high-grade histology were independently associated with lower OS. When stratified by treatment modality, there was no statistical difference in OS ( p = 0.475). Conclusions: Primary breast angiosarcoma arises in women with a median age of 40 years, and large, high-grade tumors are associated with worse survival outcomes. Distant recurrence is common, whereas nodal metastases and local failure are not. Most of the patients in this study received multimodal therapy without a clear impact of modality on OS. However, further collaborative studies may be required to assess the impact of modality on disease outcomes.
- 10 September 2026
- Published by Elsevier in Journal of Surgical Education
- Vol. 83  (11) , 104169
Trends in Surgical Specialty Fellowship Applications in the Era of COVID-19 and Virtual Interviewing
- 10 September 2026
- Published by Elsevier in Journal of Surgical Education
- Vol. 83  (11) , 104169
Trends in Surgical Specialty Fellowship Applications in the Era of COVID-19 and Virtual Interviewing
- 22 June 2026
- Published by Wolters Kluwer Health in Annals of Surgery
- Vol. 284  (3) , 647-657
5x-Multiplier Versus 3-Tier Model
Background: Standardized prescribing models can reduce discharge opioid prescription and excess pill volumes, mitigating potential opioid dependence and diversion after abdominal operations. This studyâs objective was to determine which of 2 validated discharge prescribing models resulted in fewer opioids prescribed and consumed after major abdominal surgery. Methods: This was a pragmatic single-center, phase II randomized clinical trial comparing 2 discharge opioid prescribing models: linear 5x-multiplier algorithm (last-24hrs oral morphine equivalents [OME] times 5) versus capped 3-tier model (5/15/30 pills depending on 0/1-29/âĽ30 mg OME in last-24hrs). Adults undergoing open abdominal cancer resections by 25 surgeons (5 specialties) were included. A non-opioid analgesic bundle was used perioperatively and at discharge. Co-primary endpoints were discharge opioid volume and 14-day post-discharge consumption. Secondary endpoints included patient satisfaction and symptom inventory. The power (80%) calculation was performed using the two-sample t-test to detect a mean difference in OME with 0.05 significance (0.025 per co-primary outcomes). Results: From April-December 2024, 150 patients (52% female; median age 63) were randomized: 73 to 5x-multiplier; 77 to 3-tier model. Operations included hepatectomy (32%), pancreatectomy (29%), nephrectomy (13%), thoracoabdominal sarcoma resection (15%), and ovarian cytoreduction (11%). Median discharge OME was 25 mg (5x-multiplier) versus 75mg (3-tier, P P =0.496). Refill rates were 24% (5x-multiplier) versus 18% (3-tier, P =0.426), consistent with historical rates, with no differences in satisfaction or symptom inventory scores. Conclusion: The 5x-multiplier algorithm resulted in fewer prescribed discharge opioids with similar 14-day consumption, refill rates, and satisfaction, compared to a 3-tier model after intra-abdominal cancer surgery.
- 22 June 2026
- Published by Wolters Kluwer Health in Annals of Surgery
- Vol. 284  (3) , 647-657
5x-Multiplier Versus 3-Tier Model
Background: Standardized prescribing models can reduce discharge opioid prescription and excess pill volumes, mitigating potential opioid dependence and diversion after abdominal operations. This studyâs objective was to determine which of 2 validated discharge prescribing models resulted in fewer opioids prescribed and consumed after major abdominal surgery. Methods: This was a pragmatic single-center, phase II randomized clinical trial comparing 2 discharge opioid prescribing models: linear 5x-multiplier algorithm (last-24hrs oral morphine equivalents [OME] times 5) versus capped 3-tier model (5/15/30 pills depending on 0/1-29/âĽ30 mg OME in last-24hrs). Adults undergoing open abdominal cancer resections by 25 surgeons (5 specialties) were included. A non-opioid analgesic bundle was used perioperatively and at discharge. Co-primary endpoints were discharge opioid volume and 14-day post-discharge consumption. Secondary endpoints included patient satisfaction and symptom inventory. The power (80%) calculation was performed using the two-sample t-test to detect a mean difference in OME with 0.05 significance (0.025 per co-primary outcomes). Results: From April-December 2024, 150 patients (52% female; median age 63) were randomized: 73 to 5x-multiplier; 77 to 3-tier model. Operations included hepatectomy (32%), pancreatectomy (29%), nephrectomy (13%), thoracoabdominal sarcoma resection (15%), and ovarian cytoreduction (11%). Median discharge OME was 25 mg (5x-multiplier) versus 75mg (3-tier, P P =0.496). Refill rates were 24% (5x-multiplier) versus 18% (3-tier, P =0.426), consistent with historical rates, with no differences in satisfaction or symptom inventory scores. Conclusion: The 5x-multiplier algorithm resulted in fewer prescribed discharge opioids with similar 14-day consumption, refill rates, and satisfaction, compared to a 3-tier model after intra-abdominal cancer surgery.
- 6 April 2026
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 33  (6) , 4891-4893
Complex General Surgical Oncology (CGSO) Entrustable Professional Activities: An Opportunity for Mixed-Methods Longitudinal Feedback
- 6 April 2026
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 33  (6) , 4891-4893
Complex General Surgical Oncology (CGSO) Entrustable Professional Activities: An Opportunity for Mixed-Methods Longitudinal Feedback
- Open Access
- 2 February 2026
- Published by MDPI AG in Current Oncology
- Vol. 33  (2) , 90
The Impact of Vascular Management on Postoperative Complications in Patients Undergoing Surgery for Retroperitoneal Leiomyosarcoma
Background: Retroperitoneal leiomyosarcomas are aggressive malignancies. Complete surgical resection with negative margins is crucial to decrease the risk of recurrence but can be risky due to vascular involvement. The aim of our study was to evaluate the different approaches to IVC and renal vein management and their impact on postoperative complications. Methods: We performed a retrospective review of patients who underwent surgery for retroperitoneal leiomyosarcoma with IVC and/or renal vein involvement at our institution from 2016 to 2024. Patients were stratified by intraoperative vascular management, including ligation only versus varying forms of vascular reconstruction. Postoperative complications, including bleeding, transfusions, the need for acute and chronic hemodialysis, and thromboembolic events, were recorded. Chi-squared tests were used to compare rates of postoperative complications by vascular management. A p-value of 0.05 was considered statistically significant. Results: We identified 60 patients at our institution who underwent surgery for leiomyosarcoma with IVC and/or renal vein involvement. Ten patients underwent IVC ligation alone due to thrombosis, thirty-six had IVC replacement, and fourteen had patch angioplasty. In the entire cohort, twenty-six patients (43.3%) experienced an adverse event after surgery. When looking at postoperative adverse events by IVC management, we did not find any statistically significant differences among rates of adverse events by group. There were also no statistically significant differences in complications following renal vein ligation versus renal vein reconstruction. Conclusions: Patients with leiomyosarcoma with IVC and/or renal vein involvement have several options for intraoperative vascular management. Our data demonstrates that there are no statistically significant differences in rates of complications among the different groups.
- 2 February 2026
- Published by MDPI AG in Current Oncology
- Vol. 33  (2) , 90
Open AccessThe Impact of Vascular Management on Postoperative Complications in Patients Undergoing Surgery for Retroperitoneal Leiomyosarcoma
Background: Retroperitoneal leiomyosarcomas are aggressive malignancies. Complete surgical resection with negative margins is crucial to decrease the risk of recurrence but can be risky due to vascular involvement. The aim of our study was to evaluate the different approaches to IVC and renal vein management and their impact on postoperative complications. Methods: We performed a retrospective review of patients who underwent surgery for retroperitoneal leiomyosarcoma with IVC and/or renal vein involvement at our institution from 2016 to 2024. Patients were stratified by intraoperative vascular management, including ligation only versus varying forms of vascular reconstruction. Postoperative complications, including bleeding, transfusions, the need for acute and chronic hemodialysis, and thromboembolic events, were recorded. Chi-squared tests were used to compare rates of postoperative complications by vascular management. A p-value of 0.05 was considered statistically significant. Results: We identified 60 patients at our institution who underwent surgery for leiomyosarcoma with IVC and/or renal vein involvement. Ten patients underwent IVC ligation alone due to thrombosis, thirty-six had IVC replacement, and fourteen had patch angioplasty. In the entire cohort, twenty-six patients (43.3%) experienced an adverse event after surgery. When looking at postoperative adverse events by IVC management, we did not find any statistically significant differences among rates of adverse events by group. There were also no statistically significant differences in complications following renal vein ligation versus renal vein reconstruction. Conclusions: Patients with leiomyosarcoma with IVC and/or renal vein involvement have several options for intraoperative vascular management. Our data demonstrates that there are no statistically significant differences in rates of complications among the different groups.
- Open Access
Sugammadex Versus Neostigmine in Return to Intended Oncological Therapy After Gastrointestinal Cancer Surgery: A Retrospective Study
Background: Adjuvant therapies improve disease-free and cancer-specific survival in digestive tract malignancies. Return to intended oncological therapy (RIOT) measures how promptly patients resume these treatments after cancer resection. Because sugammadex has demonstrated superior postoperative outcomes compared to neostigmine, we hypothesize that its use may increase the likelihood and timeliness of RIOT in patients undergoing digestive tract cancer surgery. Methods: Adults (âĽ18 years) undergoing gastrointestinal, hepatobiliary cancer resection, or liver resection for limited metastases between January 2016 and December 2017 were retrospectively analyzed. Patients were grouped by neuromuscular blockade reversal agent (neostigmine vs. sugammadex). The primary outcome was RIOT within 90 days; secondary outcomes included RIOT within 180 days, time-to-RIOT, hospital length of stay, ICU admission, and readmissions. Results: Of 4358 records screened, 1081 met the inclusion criteria: 273 (25.2%) patients with neostigmine and 808 (74.8%) with sugammadex. Patients in the neostigmine group were slightly younger, and racial distribution differed modestly, but sex, BMI, ASA class, comorbidity, cancer type, and stage were comparable. Median reversal doses were 5 mg and 200 mg, respectively. Anesthesia duration, hospital and ICU length of stay, readmissions, and ICU use showed no significant differences. RIOT frequency was also similar across groups, except for modestly higher radiotherapy resumption with neostigmine at 90 and 180 days. Overall, perioperative and oncological outcomes were largely comparable between groups. Conclusions: Sugammadex and neostigmine showed similar RIOT rates, with only a modest difference in radiotherapy resumption. Larger studies are needed to elucidate the potential benefits of sugammadex, particularly regarding long-term oncological outcomes and treatment continuity.
Open AccessSugammadex Versus Neostigmine in Return to Intended Oncological Therapy After Gastrointestinal Cancer Surgery: A Retrospective Study
Background: Adjuvant therapies improve disease-free and cancer-specific survival in digestive tract malignancies. Return to intended oncological therapy (RIOT) measures how promptly patients resume these treatments after cancer resection. Because sugammadex has demonstrated superior postoperative outcomes compared to neostigmine, we hypothesize that its use may increase the likelihood and timeliness of RIOT in patients undergoing digestive tract cancer surgery. Methods: Adults (âĽ18 years) undergoing gastrointestinal, hepatobiliary cancer resection, or liver resection for limited metastases between January 2016 and December 2017 were retrospectively analyzed. Patients were grouped by neuromuscular blockade reversal agent (neostigmine vs. sugammadex). The primary outcome was RIOT within 90 days; secondary outcomes included RIOT within 180 days, time-to-RIOT, hospital length of stay, ICU admission, and readmissions. Results: Of 4358 records screened, 1081 met the inclusion criteria: 273 (25.2%) patients with neostigmine and 808 (74.8%) with sugammadex. Patients in the neostigmine group were slightly younger, and racial distribution differed modestly, but sex, BMI, ASA class, comorbidity, cancer type, and stage were comparable. Median reversal doses were 5 mg and 200 mg, respectively. Anesthesia duration, hospital and ICU length of stay, readmissions, and ICU use showed no significant differences. RIOT frequency was also similar across groups, except for modestly higher radiotherapy resumption with neostigmine at 90 and 180 days. Overall, perioperative and oncological outcomes were largely comparable between groups. Conclusions: Sugammadex and neostigmine showed similar RIOT rates, with only a modest difference in radiotherapy resumption. Larger studies are needed to elucidate the potential benefits of sugammadex, particularly regarding long-term oncological outcomes and treatment continuity.
- 28 May 2025
- Published by Wolters Kluwer Health in Annals of Surgery
- Vol. 282  (2) , 184-185
Can Women Surgeons Have It All? If Not Now, When?
An abstract is unavailable. This article is available as a PDF only.
- 28 May 2025
- Published by Wolters Kluwer Health in Annals of Surgery
- Vol. 282  (2) , 184-185
Can Women Surgeons Have It All? If Not Now, When?
An abstract is unavailable. This article is available as a PDF only.
- Open Access
- 1 May 2025
- Published by UT MD Anderson Cancer Center Research Medical Library in Advances in Cancer Education and Quality Improvement
- Vol. 1  (1) , 19
5x-Multiplier vs 3-Tier Model for Discharge Opioid Prescriptions After Intra-Abdominal Cancer Surgery: Randomized Clinical Trial Protocol
Background Surgeons provide up to 10% of total opioid prescriptions across all specialties, and more than one-third of surgeon-prescribed medications are opioids. Patient-reported opioid consumption and risk of persistent opioid use beyond the postoperative recovery period correlate with the initial opioid quantity prescribed at discharge. Interventions to reduce postoperative opioid prescribing have demonstrated no adverse effects on pain control or increased need for prescription refill; however, in the absence of standardized prescription protocols, opioid prescribing practices vary widely. Objective The study objective is to identify the opioid prescribing model that provides the lowest oral morphine equivalents (OME) volume prescribed at discharge and OME consumed in the 14 days after discharge, with no adverse effect on refills and patient quality of life or satisfaction. Methods and Analysis This is a pragmatic single-center, multispecialty, double-arm phase II randomized clinical trial of two discharge opioid prescribing models. All adult (âĽ18 years) patients who undergo any one of five open abdominal oncologic operations (pancreatectomy, hepatectomy, retroperitoneal sarcoma resection, nephrectomy, or cytoreductive surgery for ovarian cancer) with curative intent and have a planned postoperative inpatient stay of at least 48 hours will be eligible. Patients will be stratified by their managing clinical service and randomized to receive a discharge opioid prescription based on either the 5x-multiplier algorithm or the 3-tier model. The co-primary outcomes are initial discharge OME volume and OME consumption in the 14 days after hospital discharge. Secondary outcomes include rates of patients with zero OME at discharge; rates of refill requests and completions, number of unused or leftover pills, persistent opioid use, and patient-reported quality-of-life metrics at various follow-up times; patient, prescriber, and oncologic factors predictive of persistent opioid use; and patient satisfaction. Each co-primary endpoint will be analyzed using two-sample t-test to compare means and linear regression models to assess differences between the two arms. Ethics and Dissemination This study was approved by the Institutional Review Board of The University of Texas MD Anderson Cancer Center (2023-0818). The study will evaluate the difference in initial discharge OME volume and in 14-day post-discharge OME consumption between two discharge opioid prescribing models. Upon completion of the data collection and analyses, a manuscript describing the study results will be submitted to a peer-reviewed journal for publication and dissemination. Trial Registration Number: NCT06232577.
- 1 May 2025
- Published by UT MD Anderson Cancer Center Research Medical Library in Advances in Cancer Education and Quality Improvement
- Vol. 1  (1) , 19
Open Access5x-Multiplier vs 3-Tier Model for Discharge Opioid Prescriptions After Intra-Abdominal Cancer Surgery: Randomized Clinical Trial Protocol
Background Surgeons provide up to 10% of total opioid prescriptions across all specialties, and more than one-third of surgeon-prescribed medications are opioids. Patient-reported opioid consumption and risk of persistent opioid use beyond the postoperative recovery period correlate with the initial opioid quantity prescribed at discharge. Interventions to reduce postoperative opioid prescribing have demonstrated no adverse effects on pain control or increased need for prescription refill; however, in the absence of standardized prescription protocols, opioid prescribing practices vary widely. Objective The study objective is to identify the opioid prescribing model that provides the lowest oral morphine equivalents (OME) volume prescribed at discharge and OME consumed in the 14 days after discharge, with no adverse effect on refills and patient quality of life or satisfaction. Methods and Analysis This is a pragmatic single-center, multispecialty, double-arm phase II randomized clinical trial of two discharge opioid prescribing models. All adult (âĽ18 years) patients who undergo any one of five open abdominal oncologic operations (pancreatectomy, hepatectomy, retroperitoneal sarcoma resection, nephrectomy, or cytoreductive surgery for ovarian cancer) with curative intent and have a planned postoperative inpatient stay of at least 48 hours will be eligible. Patients will be stratified by their managing clinical service and randomized to receive a discharge opioid prescription based on either the 5x-multiplier algorithm or the 3-tier model. The co-primary outcomes are initial discharge OME volume and OME consumption in the 14 days after hospital discharge. Secondary outcomes include rates of patients with zero OME at discharge; rates of refill requests and completions, number of unused or leftover pills, persistent opioid use, and patient-reported quality-of-life metrics at various follow-up times; patient, prescriber, and oncologic factors predictive of persistent opioid use; and patient satisfaction. Each co-primary endpoint will be analyzed using two-sample t-test to compare means and linear regression models to assess differences between the two arms. Ethics and Dissemination This study was approved by the Institutional Review Board of The University of Texas MD Anderson Cancer Center (2023-0818). The study will evaluate the difference in initial discharge OME volume and in 14-day post-discharge OME consumption between two discharge opioid prescribing models. Upon completion of the data collection and analyses, a manuscript describing the study results will be submitted to a peer-reviewed journal for publication and dissemination. Trial Registration Number: NCT06232577.